1. Introduction {#sec1}
===============

Smallpox was a devastating contagious disease that ravaged humankind for millennia, wiping out entire civilizations \[[@B1]\]. The disease was caused by two types of variola virus (VARV), major and minor, which differed greatly in their average mortality rates: 30% versus 1%, respectively. VARV major was the most prevalent form \[[@B2], [@B3]\]. Systematic vaccination against smallpox began in the early 19th century but the disease lingered until the World Health Organization (WHO) initiated worldwide vaccination campaigns in 1967. The last case was reported in Somalia in 1977 and in May 1980 the WHO declared that smallpox had been eradicated, ceasing vaccination \[[@B1], [@B2]\]. Eradication was facilitated because there are no animal reservoirs for the virus, as it only infects humans \[[@B4]\].

VARV belongs to the*Orthopox* genus of the*Poxviridae* family, consisting of large double-stranded DNA viruses that replicate in the cytoplasm of infected cells \[[@B5], [@B6]\]. Poxviruses are large and complex with \~250 genes and a multistage life cycle, producing different infective forms including intracellular mature virions (IMV) and extracellular enveloped virus (EEV) \[[@B5], [@B6]\]. Humans can be infected by several poxviruses; the closest to VARV that are also pathogenic to humans are vaccinia (VACV), cowpox (CPXV), and monkeypox (MPXV) viruses \[[@B7], [@B8]\]. The primary reservoir of MPXV is rodents \[[@B9]\], while CPXV has the broadest animal reservoir range of all poxvirus, including cats, dogs, elephants, and rodents \[[@B10]\]. Historically, VAVC has been considered to emerge after repeated passages from an ancestral CPXV \[[@B11]\]. However, phylogenetic studies question that view and there are some speculations that VACV could be a horsepox virus (HPXV) \[[@B12]\]; yet both, the host and origin of VACV, remain unknown \[[@B13]\]. VACV and CPXV infections in humans are generally mild and self-limiting and can induce cross-protective immunity \[[@B14]\]. The observation that CPXV sufferers did not get smallpox led Edward Jenner in 1798 to introduce a method of vaccination through scarifications with*Variolae Vaccinae*, Latin, for CPXV \[[@B15]\]. Immunization with CPXV was eventually displaced by VACV vaccine, which was used subsequently for global smallpox vaccination \[[@B12]\].

As smallpox was eradicated and vaccination ceased, the global population has become increasingly susceptible to both smallpox and zoonosis by orthopoxviruses \[[@B8], [@B9]\]. People under 30 have no immunity against these viruses and VACV-induced immunity is waning in those that were vaccinated \[[@B16]\]. Despite recommendations by the WHO, stockpiles of smallpox virus had never been destroyed and there are concerns that unregistered stocks could be used as a weapon of bioterrorism \[[@B17]\]. Several features make smallpox a major terrorist threat. It replicates easily, is aerosolizable, and is highly contagious before, during, and after disease onset. Moreover, smallpox is lethal and disfiguring and has already been used as a biological weapon in North America during the French and Indian Wars \[[@B18]\]. Thus, there is renewed interest in the development of vaccines against smallpox, particularly safer ones, since immunization with VACV can result in serious adverse events and it is considered risky in immunocompromised or immune-suppressed individuals \[[@B19]\].

Immune protection against orthopoxviruses requires both B and T cells \[[@B20]\] but the relevance of T cells is paramount. CD8 T cells are required to eliminate infected cells, while help by CD4 T cells is essential to elicit effective humoral responses \[[@B21]\]. Thus, people with dysfunctional humoral responses (e.g., agammaglobulinemia) can be vaccinated with VACV, while those with loss of T cells cannot as they can suffer severe disease \[[@B22]\]. T-cell immune responses are triggered by the recognition of foreign peptides bound to cell surface-expressed major histocompatibility complex (MHC) molecules, also known as human leukocyte antigens, HLA, in humans. CD4 T cells recognize peptides presented by MHC class II (MHC II) molecules while CD8 T cells recognize peptides presented by MHC class I (MHC I) molecules.

Advances in both immunology and genomic analysis offer new possibilities for eliciting immune protection without the requirement for live-virus vaccination and attendant complications. The identification of HLA class I and class II restricted T-cell epitopes (CD8 and CD4 T-cell epitopes, resp.) from poxviruses may allow us to develop safe and yet immunogenic peptide-based vaccines. Here, we describe the identification of protein antigens that are shared between several pathogenic orthopoxviruses, including VARV, MPXV, CPXV, and VACV, and T-cell epitopes that are identical in all selected proteins. This information was used to create a freely accessible web resource, EPIPOX: URL <http://imed.med.ucm.es/epipox/>, intended to facilitate the design of epitope-based vaccines against orthopoxviruses.

2. Materials and Methods {#sec2}
========================

2.1. Orthopoxvirus Sequences and Experimentally Defined T-Cell Epitopes {#sec2.1}
-----------------------------------------------------------------------

In this study, we used the entire proteomes of 8 orthopoxviruses: VARV major, strain Bangladesh-1975, GenBank Accession: GB: L22579; VARV major, strain India-1967, GB: NC_00161; Variola major minor, strain Garcia-1966, GB: Y16780; Monkeypox virus, strain Zaire-96-I-16, GB: NC_003310; Cowpox virus strain, strain Brighton Red, GB: AF482758, Vaccinia virus, strain Copenhagen, GB: M35027; Vaccinia virus, strain Tian Tan, GB: AF095689; Vaccinia virus, strain Ankara, GB: U94848. The proteomes were obtained from the various translation features of the relevant GenBank genomic records using BIOPERL \[[@B23]\] ([Table 1](#tab1){ref-type="table"}).

We also used experimentally defined poxvirus-specific HLA I and HLA II-restricted T-cell epitopes that were retrieved from the IEDB \[[@B24]\] and EPIMHC \[[@B25]\] databases. We only considered unique T-cell epitope sequences with a size of 9 amino acids that were reported to be identified in humans infected with orthopoxviruses or who were vaccinated. We provide a list of experimentally defined T-cell epitopes as supplementary material in Additional File S1 in Supplementary Material available online at <http://dx.doi.org/10.1155/2015/738020>.

2.2. Protein Sequence Analyses and Annotations {#sec2.2}
----------------------------------------------

We took VARV major, strain Bangladesh-1975, as the reference for subsequent sequence analyses. We identified proteins with leader signals using SIGNALP \[[@B26]\] and transmembrane regions using TMHMM \[[@B27]\]. We identified protein orthologs using BLAST \[[@B27]\]. Briefly, we first BLAST the reference proteins against formatted databases of each of the remaining orthopoxvirus proteomes. We performed BLAST searches with default settings and considered only the description of the first hit and the corresponding alignment. Subsequently, we selected those protein searches that gave hits in each of the proteomes with identities greater than 60% and identified the corresponding orthologs. We used BIOPERL to parse BLAST hits \[[@B23]\].

Information on the temporal expression of VACV genes was kindly provided by Dr. Lefkowitz from the Poxvirus Bioinformatics Resource Center \[[@B29]\]. The information consisted on annotations identifying those genes that are expressed early (E), intermediate (I), and late (L) during the life cycle of VACV. This information is provided as supplementary material in Additional File S2. In addition, we identified, from the data provided by Dr. Lefkowitz, gene products associated with the outer membranes of VACV IMV and EEV infective forms, as well as those proteins that are part of the VACV virion or CORE. This information is also included as supplementary material in Additional File S2. Protein annotations obtained for VACV were transferred to protein orthologs.

2.3. Prediction of T-Cell Epitopes {#sec2.3}
----------------------------------

We predicted MHC I and MHC II peptide binding to anticipate potential CD8 and CD4 T-cell epitopes, respectively. Specifically, we predicted peptide-MHC binding from VARV Bangladesh proteins that are shared between all selected orthopoxviruses using 32 HLA I- and 33 HLA II-allele specific position-specific scoring matrices (PSSMs) \[[@B30]--[@B32]\]. For a given protein, we considered the top 2% and 4% of scoring peptides to constitute HLA I- and HLA II-binding peptides, respectively. We only predicted binding for peptides of nine residues; most HLA I-restricted peptides are 9 residues in length and while HLA II-restricted peptides vary in length (9--22 amino acids) they have a core of 9 residues that anchor the peptide in the binding groove of HLA II molecules \[[@B31], [@B33]\]. We also used N-gram language models to identify whether peptides can be generated from the source antigen by proteasomal cleavage \[[@B34]\]. This information is only relevant to HLA I-binding peptides, since most peptides presented by MHC I are derived from antigens degraded by the proteasome \[[@B35]\].

2.4. Database Building and Web Server Implementation {#sec2.4}
----------------------------------------------------

Predicted T-cell epitopes and obtained protein annotations were incorporated into a POSTGRES relational database. The database consists of 3 tables (*peptides*,*predictions*, and*proteins*) that are linked through unique keys ([Figure 1](#fig1){ref-type="fig"}). Briefly, table*predictions* contains peptide sequences and their MHC restriction elements; table*peptides* includes the peptide molecular weight, its protein accession number, and whether the peptide is cleaved by the proteasome; and table*proteins* contains gene product information including temporal expression (E: early, I: intermediate, and L:late), location in the virus (IMV, EEV, and CORE), and the existence of leader and transmembrane regions. We also developed a web front end or GUI to allow ready access to EPIPOX. Behind the interface is a Python script that handles database queries through underlying SQL. The EPIPOX resource is implemented on an Apache Web server under the Mac OSX operating system.

3. Results and Discussion {#sec3}
=========================

3.1. Epitope-Vaccine Design against Orthopoxviruses {#sec3.1}
---------------------------------------------------

T-cell adaptive immunity is required for clearance of poxviruses during infection and/or vaccination and can also contribute to protective immunity from subsequent exposures \[[@B36], [@B37]\]. Moreover, peptides corresponding to VACV-specific CD8 T-cell epitopes can confer protection to mice subjected to lethal VACV challenges \[[@B38]\]. Fueled by the need to develop safer smallpox vaccines, such knowledge has led to the recent identification of many VACV-specific T-cell epitopes \[[@B38], [@B39]\]. These T-cell epitopes are deposited haphazardly in various specialized databases, including IEDB \[[@B24]\], EPIMHC \[[@B25]\], TEPIDAS \[[@B40]\], and AntiJen \[[@B41]\]. Of relevance for epitope-vaccine design, CD8 T-cells target primarily early and nonstructural gene products \[[@B42], [@B43]\]. CD4 T cells target late and the most abundant genes products (IMV and EEV membrane proteins and CORE proteins), as do antibodies \[[@B43], [@B44]\]. While some of the identified VAVC-specific T-cell epitopes are conserved in VARV a rational approach to identifying all potential T-cell epitopes eliciting cross-protective immunity is still required.

3.2. Shared Orthopoxvirus Proteins for Cross-Protective Immunity {#sec3.2}
----------------------------------------------------------------

Nearly all orthopoxviruses can protect against challenge with another orthopoxvirus \[[@B14]\]. This exquisite cross-protective immunity is likely a result of direct antigenic similarity between poxviruses. Therefore, prior to defining potential T-cell epitopes we identified shared antigens between pathogenic orthopoxviruses. Identification of shared antigens is also relevant to reducing the experimental burden associated with T-cell identification. Human pathogen orthopoxviruses have large genomes encompassing over 180 open reading frames (ORF) with the exception of VACV Ankara strain, which has only 157 genes and lacks the ability to replicate \[[@B45]\] ([Table 1](#tab1){ref-type="table"}). Using VARV major, strain Bangladesh-1975, as a reference, we identified 124 ORFs that are shared between 8 different complete genomes from several orthopoxviruses, including VARV minor, CPXV, MPXV, and several VACV strains (Additional File S3). Despite the criterion for selection being 60% identity, all 124 selected proteins have an average identity ≥ 85% as shown in Additional File S3. These proteins are prime candidates to induce cross-protective immunity although they need to be targeted by the immune system. Interestingly, within the selected proteins there are 8 known immunogens that conferred \>60% protection to VACV in animal models ([Table 2](#tab2){ref-type="table"}) \[[@B46]\]. Six of these immunogens are IMV or EEV proteins carrying transmembrane regions and/or are being late gene products. Interestingly, among the selected 124 proteins we found 26 additional proteins with transmembrane regions that could also be prime vaccine subunits candidates ([Table 3](#tab3){ref-type="table"}). Some of these proteins also have leader signal sequences ([Table 3](#tab3){ref-type="table"}). Viral proteins with leader sequences follow the cell secretory pathway and are thus also important targets to consider for vaccine design \[[@B47], [@B48]\].

3.3. T-Cell Epitome from Pathogenic Orthopoxvirus Proteins {#sec3.3}
----------------------------------------------------------

We targeted the shared orthopoxvirus proteins for T-cell epitopes prediction using 32 and 33 HLA I- and HLA II-specific profile matrices (details in Material and Methods). The alleles targeted for peptide binding prediction are shown in Additional File S4. We selected these alleles because there are experimental peptide-binding data for them, which is required to make accurate peptide-MHC binding predictors \[[@B49]\]. Incidentally, these HLA alleles are frequently expressed in the general population and targeting them for epitope prediction permits the development of epitope-based vaccines covering the entire population. These HLA allelic variants can have overlapping peptide-binding repertoires and can be clustered accordingly in supertypes \[[@B50], [@B51]\]. Selecting promiscuous peptide-binders to multiple HLA molecules facilitates the development of vaccines with a minimum number of peptides \[[@B50]--[@B52]\].

We predicted a total of 18726 HLA I-restricted and 32722 HLA II-restricted orthopoxvirus specific T-cell epitopes, all being identical between all orthopoxviruses considered in this study. In Additional File S4 we provide numbers of T-cell epitopes predicted by each HLA-specific profile used in this study. We predicted more CD4 than CD8 T-cell epitopes because we used a more permissive peptide-binding threshold for MHC II molecules (4% of top scoring peptides) than for MHC I molecules (2% of top scoring peptides) since peptide-binding prediction to MHC II molecules is considerably less accurate than to MHC I molecules \[[@B47]\]. Interestingly, we identified only 8106 unique HLA I-restricted T-cell epitope sequences and a few more (8483) unique HLA II-restricted T-cell epitope sequences. Therefore, there is a considerable overlap between the peptide binding repertoires of HLA molecules, which is larger for HLA II molecules than for HLA I molecules. HLA I-restricted peptides bound on average to 2.3 distinct HLA I molecules, while HLA II-restricted peptides bound on average to 3.8 distinct HLA II molecules. This is due to the fact that peptide-binding to MHC II molecules is more degenerate than to MHC I molecules \[[@B30], [@B31]\]. In Additional File S5, we provide all distinct predicted peptides with the HLA molecules that they were predicted to bind. Interestingly, there is also some overlap between HLA I- and HLA II-restricted peptides. In particular, we find that there are 2452 peptides that are predicted to be restricted by both HLA I and HLA II molecules. Thus, in total the predicted T-cell epitome consisted of just 14137 unique sequences among all predicted T-cell epitopes.

We compared the predicted T-cell epitome with experimentally defined poxvirus-specific HLA-restricted T-cell epitopes deposited in the IEDB \[[@B24]\] and EPIMHC \[[@B25]\]. We retrieved 170 HLA I and 9 HLA II-restricted T-cell epitopes meeting our criteria (see Additional File S1) but we only considered for comparison 85 HLA I- and 8 HLA II-restricted T-cell epitopes that we identified here to be conserved in all orthopoxviruses considered in this study. Of those, 72 HLA I- and 6 HLA II-restricted T-cell epitopes were found within our predicted T-cell epitome. Moreover, we predicted the experimentally verified restriction element in \> 80%. The experimentally determined and shared epitopes that were not predicted (a minority) either are restricted by noncovered alleles or were simply not predicted. In [Table 4](#tab4){ref-type="table"}, we summarize the data showing the verified and predicted HLA restriction elements. In sum, we readily predicted most of the experimentally verified T-cell epitopes. Considering that on average 10% of predicted T-cell epitopes can be experimentally verified \[[@B53]\], we shall expect that there are many more valid T-cell epitopes remaining to be validated within the T-cell epitome predicted in this study.

3.4. EPIPOX Database and Web Server {#sec3.4}
-----------------------------------

We developed a relational database based upon the predicted T-cell epitome and a web-based resource to facilitate online access and to query the database. We named this resource EPIPOX and made it available for free public use (URL: <http://imed.med.ucm.es/epipox/>). EPIPOX is a*de facto* analysis pipeline of viral T-cell epitomes. The content of the EPIPOX database is organized in three tables (*peptides*,*predictions*, and*proteins*) ([Figure 1](#fig1){ref-type="fig"}). The table*predictions* contains all predicted T-cell epitopes, consisting of 18726 HLA I- and 32722 HLA II-restricted peptides, each identified by its sequence and restriction element. Peptide sequences in this table are not unique as each peptide can bind to numerous HLA I molecules. Peptide sequences are, however, unique in the table*peptides.*This table contains 14137 sequences comprising the whole predicted epitome regardless of the restriction elements. Antigen annotations in EPIPOX are found within the table*proteins* ([Figure 1](#fig1){ref-type="fig"}). We only included annotations that are relevant to epitope vaccine design, such as temporal expression of gene products and location in relevant structures of the virus such as the EEV and IVM membranes and CORE. Early expressed proteins and highly expressed proteins are generally thought to be more immunogenic, particularly with regard to CD8 T cells \[[@B54], [@B55]\]. On the other hand, highly abundant late proteins that are located in membrane structures of the poxvirus appear to be the main focus of the antibody and CD4 T-cell response \[[@B43], [@B44]\]. In the table*proteins*, we also provide annotations on whether the proteins have transmembrane region or leader signal sequence, as proteins with these features often interact with host cells and are important targets for subunit vaccine design \[[@B47], [@B48]\].

The EPIPOX web interface ([Figure 2](#fig2){ref-type="fig"}) allows querying of the database combining any annotation field in the database, as described above. For intuitive use, the interface is divided in two main sections. In the first section (SEARCH), users select proteins and restriction elements for epitope retrieval. In this section, EPIPOX also provides the option to query the database for promiscuous T-cell epitopes binding to three HLA I supertypes (A2, A3, and B7). The alleles belonging to these supertypes are present in 88% of the population regardless of their ethnic groups. Selecting promiscuous peptides restricted by these 3 supertypes facilitates maximizing the population coverage of vaccines with minimum numbers of peptides \[[@B50], [@B51], [@B56]\]. In the second section (LIMIT), users can select annotation criteria to restrict the results. As an example, in [Figure 3](#fig3){ref-type="fig"}, we show the page resulting from a sample query consisting of promiscuous peptides from CORE binding to the A2 supertype. From the EPIPOX output, users can also access additional information available from the Virus Pathogen Resource database ([Figure 3](#fig3){ref-type="fig"}) \[[@B57]\].

EPIPOX is related somewhat to certain existing databases. On the one hand, it shares features with generic epitope databases such as EPIMHC \[[@B25]\], AntiJen \[[@B41]\], and IEDB \[[@B24]\] and on the other hand it shares features with poxvirus genome annotation-orientated databases such as the *Poxviridae* database \[[@B29]\] (no longer operating) and the Virus Pathogen Resource (<http://www.viprbrc.org/>) \[[@B57]\]. This later resource contains information on virus sequences, functional annotations and epitopes derived from IEDB \[[@B24]\]. However, the Virus Pathogen Resource does not allow selection of epitopes or antigens by criteria that are relevant to epitope vaccine design. In fact, EPIPOX is the only dedicated immunologic resource that has been designed to facilitate the rational selection of epitopes and antigens for subunit vaccine design.

4. Conclusions and Future Development {#sec4}
=====================================

The availability of the VARV genomes enables the use of predictive tools that reveal entire T-cell epitomes and facilitate the development of epitope-based vaccines. However, in large and complex viruses, such as VARV, the potential T-cell epitome can be so sizeable that it will challenge experimental validation. Therefore, in this work we applied a rational strategy to limit the list of potential T-cell epitopes. First, we reduced the number of antigens by half by simply selecting those that are conserved among pathogenic orthopoxviruses related to VARV. Second, we enriched the antigens with annotations such as temporal expression and location. Lastly, we created a resource and*de facto* analysis pipeline (EPIPOX) with which to interrogate the resulting T-cell epitome and enable users to select immunologically relevant subsets of T-cell epitopes suitable for experimental validation.

We expect that this work and EPIPOX will be instrumental in developing safer smallpox vaccines and thereby in preventing zoonosis caused by other orthopoxviruses, including MPXV, which is also a potential terrorist bioweapon. In the future, we plan to enhance EPIPOX with validated and/or experimentally determined epitopes, upgrade protein annotations with functional information, and include additional features such as TAP transport \[[@B58]\], ERAAP cleavage \[[@B59]\], and T-cell epitope immunodominance. In sum, we would expect EPIPOX to establish itself as a facilitating resource of true utility in*inter alia* immunoinformatic characterization of viral genomics and computational reverse vaccinology.

Supplementary Material {#supplementary-material-sec}
======================

###### 

The supplementary materials provide relevant data collected and resulting from this work. Additional File S1 provides a list of experimentally determined poxvirus-specific T cell epitopes collected from relevant databases. For each epitope sequence, we show the known MHC restriction elements, protein GIs and relevant literature references. Additional File 2 reports known temporal expression (E: early, I: intermediate and L:late) and location of Vaccinia virus proteins. The information was kindly provided by Dr. Elliot J Lefkowitz. Additonal File S3 shows the 124 proteins from Variola major virus, strain Bangladesh, (VARVMJ BSH), that we found to be shared by all pathogenic orthopoxviruses, indicating their counterparts and sequence identity between them. Additional File S4 identifies the HLA I- and HLA II-molecules that were targeted for epitope prediction as well as the number of peptides predicted to bind to each one of them. Finally, Additional File S5 lists all HLA Iand HLA II-restricted T-cell epitopes shared between pathogenic orthopoxviruses predicted in this study. The epitopes are ordered by the number of different HLA molecules that can present them.
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![EPIPOX database structure. EPIPOX is a relational database consisting of three main tables:*peptides*,*predictions*, and*proteins*. Table names are boxed with double lines. For each table, we show their fields and boxed with single lines the fields that work as table keys. For fields taking discrete nominal values, we show them between square brackets.](JIR2015-738020.001){#fig1}

![EPIPOX input page. The input page of EPIPOX is divided in two main sections for intuitive use. In the first part (SEARCH), users select HLA molecules and proteins to retrieve T-cell epitopes (multiple selection is allowed) while in the second part the user can limit the search output according to various criteria. These criteria include temporal expression of gene products (E: early; I: intermediate; L: late), location of proteins in relevant structures of the virus (CORE, IMV, and EEV), and the presence of leader and transmembrane regions. In addition, users can select only those peptides with a relative score above some selectable value. HLA-specific profiles used to score T-cell epitopes can reach a maximum score, which is used to set the relative score in percentage of each peptide. For HLA I-restricted epitopes, users can also restrict the search to those epitopes potentially generated by the proteasome.](JIR2015-738020.002){#fig2}

![EPIPOX result page. The figure shows a slice of the output resulting from promiscuous CORE protein peptides binding to the A2 supertype. The output consists of a tabulated list, with information on each of the fields of the search query (columns). From field*SOURCE NAME* (1), users can access proteins from the Virus Pathogen Database (<http://www.viprbrc.org/>) (1) and by clicking on the epitope sequence, field*SEQ* (2), users will get the amino acid sequence of the protein showing the peptide in bold (2).](JIR2015-738020.003){#fig3}

###### 

Orthopoxviruses used in this study.

  Virus        Strain            ACC         Genes
  ------------ ----------------- ----------- -------
  VARV major   Bangladesh-1975   L22579      189
  VARV major   India-1967        NC_00161    197
  VARV minor   Garcia-1966       Y16780      206
  MPXV         Zaire-96-I-16     NC_003310   191
  CPXV         Brighton Red      AF482758    218
  VACV         Copenhagen        M35027      262
  VACV         Tian Tan          AF095689    243
  VACV         Ankara^*∗*^       U94848      157

^*∗*^Modified strain that has lost the ability to replicate; VARV: variola virus; MPXV: monkeypox virus; CPXV: cowpox virus; VACV: vaccinia virus.

###### 

Orthopoxvirus proteins contributing to cross-protective immunity.

  VACC: GI\|ORF   VARV: GI\|ORF   MPXV: GI\|ORF    CPXV: GI\|ORF    LOC^1^/EXP^2^/TM^3^/LD^4^
  --------------- --------------- ---------------- ---------------- ---------------------------
  335424\|L1R     438991\|M1R     17974993\|M1R    20153082\|V099   IMV/late/yes/no
  335455\|D8L     439016\|F8L     17975018\|E8L    20153106\|V119   IMV/late/yes/no
  335500\|A27L    439052\|A31L    17975052\|A29L   20153143\|V156   IMV/late/no/no
  335508\|A33R    439057\|A36R    17975058\|A35R   20153149\|V162   EEV/early/yes/no
  335549\|B5R     439084\|B6R     17975080\|B6R    20153177\|V190   EEV/\#/yes/yes
  335438\|H3L     439004\|I3L     17975006\|H3L    20153094\|V107   IMV/late/yes/no
  335477\|A10L    439032\|A11L    17975034\|A11L   20153122\|V135   CORE/\#/no/no
  335341\|C7L     438926\|D11L    17974926\|D10L   20153015\|V028   U/early/no/no

Table shows GenBank identification numbers (GI) and open reading frame names (ORF) for VACC (strain Copenhagen), VARV (strain Bangladesh-1975), MPXV (strain Zaire-96-I-16), and CPXV (strain Brighton Red). ^1^LOC: location, ^2^EXP: temporal expression, ^3^TM: transmembrane, and ^4^LD: leader signal. NS: nonstructural gene. \#: information not available. U: unknown. List of proteins was obtained from \[[@B46]\]. Annotations 1, 2, 3, and 4 obtained as indicated elsewhere in [Section 2](#sec2){ref-type="sec"}.

###### 

Shared orthopoxvirus proteins with transmembrane and/or leader sequences.

  VARV GI\|ORF      MPXV GI\|ORF        CPXV GI\|ORF        VACV GI\|ORF      IDEN^1^ (%)   TM^2^   LEAD^3^   EXP^4^   LOCATION^5^
  ----------------- ------------------- ------------------- ----------------- ------------- ------- --------- -------- -------------------
  GI:439084\|B6R    GI:17975080\|B6R    GI:20153177\|V190   GI:335549\|B5R    93.1          Yes     Yes       L        EEV membrane^*∗*^
  GI:439016\|F8L    GI:17975018\|E8L    GI:20153106\|V119   GI:335455\|D8L    94.7          Yes     No        L        IMV membrane^*∗*^
  GI:438990\|H9R    GI:17974992\|G10R   GI:20153081\|V094   GI:335423\|G9R    98.1          Yes     No        L        U
  GI:438919\|D4R    GI:17974919\|D3R    GI:20153007\|V020   GI:335333\|C11R   88.8          Yes     Yes       U        U
  GI:439085\|B7R    GI:17975081\|B7R    GI:20153178\|V191   GI:335550\|B6R    93.1          Yes     No        U        U
  GI:439035\|A14L   GI:17975037\|A14L   GI:20153125\|V138   GI:335483\|A13L   88.6          Yes     No        L        IMV membrane
  GI:438946\|C8L    GI:17974949\|C10L   GI:20153036\|V049   GI:335366\|F4L    97.6          Yes     No        E        U
  GI:438977\|K5L    GI:17974979\|I5L    GI:20153068\|V081   GI:335409\|I5L    94.9          Yes     No        L        IMV membrane
  GI:438967\|E8R    GI:17974969\|F7R    GI:20153058\|V071   GI:335395\|E8R    97.4          Yes     No        L        U
  GI:439004\|I3L    GI:17975006\|H3L    GI:20153094\|V107   GI:335438\|H3L    95.8          Yes     No        L        IMV membrane^*∗*^
  GI:439014\|F6R    GI:17975016\|E6R    GI:20153104\|V117   GI:335453\|D6R    99.0          Yes     No        L        U
  GI:439003\|I2R    GI:17975005\|H2R    GI:20153093\|V106   GI:335437\|H2R    99.2          Yes     No        L        U
  GI:439056\|A35L   GI:17975057\|A34L   GI:20153148\|V161   GI:335506\|A32L   98.1          Yes     No        L        U
  GI:439000\|L5L    GI:17975002\|L5L    GI:20153090\|V103   GI:335433\|J5L    98.1          Yes     No        L        U
  GI:439058\|A37R   GI:17975059\|A36R   GI:20153150\|V163   GI:335509\|A34R   98.1          Yes     No        L        EEV membrane
  GI:438991\|M1R    GI:17974993\|M1R    GI:20153082\|V095   GI:335424\|L1R    99.2          Yes     No        L        IMV membrane^*∗*^
  GI:439057\|A36R   GI:17975058\|A35R   GI:20153149\|V162   GI:335508\|A33R   93.0          Yes     No        E        EEV membrane^*∗*^
  GI:438951\|C13L   GI:17974954\|C15L   GI:20153041\|V054   GI:335373\|F9L    97.5          Yes     No        L        U
  GI:439038\|A17L   GI:17975040\|A17L   GI:20153129\|V142   GI:335486\|A16L   97.0          Yes     No        L        U
  GI:438974\|K2L    GI:17974976\|I2L    GI:20153065\|V078   GI:335405\|I2L    99.3          Yes     No        L        U
  GI:439008\|I7R    GI:17975010\|H7R    GI:20153098\|V111   GI:335442\|H7R    95.2          Yes     No        L        U
  GI:438982\|H3L    GI:17974984\|G2L    GI:20153073\|V086   GI:335414\|G3L    95.8          Yes     No        L        U
  GI:439042\|A22L   GI:17975044\|A21L   GI:20153134\|V147   GI:335490\|A21L   96.9          Yes     No        U        U
  GI:439059\|A38R   GI:17975061\|A38R   GI:20153152\|V165   GI:335512\|A36R   92.3          Yes     No        E, L     EEV membrane
  GI:439031\|A10L   GI:17975033\|A10L   GI:20153121\|V134   GI:335476\|A9L    89.0          Yes     Yes       E, L     U
  GI:439033\|A12R   GI:17975035\|A12R   GI:20153123\|V136   GI:335481\|A11R   98.5          Yes     No        L        U
  GI:439036\|A15L   GI:17975038\|A15L   GI:20153126\|V139   GI:335484\|A14L   97.8          Yes     No        L        IMV membrane
  GI:439067\|A46R   GI:17975066\|A43R   GI:20153159\|V172   GI:335522\|A43R   92.3          Yes     Yes       U        U
  GI:439039\|A18L   GI:17975041\|A18L   GI:20153130\|V143   GI:335487\|A17L   98.0          Yes     No        L        IMV membrane
  GI:439077\|J7R    GI:17975076\|B2R    GI:20153172\|V185   GI:335539\|A56R   82.1          Yes     Yes       E, L     EEV membrane
  GI:439062\|A41L   GI:17975063\|A40L   GI:20153155\|V168   GI:335516\|A38L   94.7          Yes     Yes       U        U

Table shows GenBank identification numbers (GI) and open reading frame names (ORF) for VARV: strain Bangladesh-1975, MPXV: strain Zaire-96-I-16, CPXV: strain Brighton Red, and VACV: strain Copenhagen. ^1^IDEN: average identity between the selected proteins. ^2^TM: transmembrane. ^3^LEAD: leader signal. ^4^EXP: temporal expression (E: early, I: intermediate, and L: late). ^5^LOCATION: location. ^*∗*^Proteins known to induce protective immunity (see [Table 2](#tab2){ref-type="table"}). Annotations were obtained as indicated elsewhere in [Section 2](#sec2){ref-type="sec"}. U: information not found.

###### 

Experimentally identified T-cell epitopes within the shared T-cell epitome predicted from pathogenic orthopoxvirus proteins.

  CD8 T-cell epitopes   VARV GI   VARV ORF   Experimental HLA I restriction   Predicted HLA I restriction                                                       
  --------------------- --------- ---------- -------------------------------- ----------------------------- ------------ ------------ ------------ ------------ ------------
  `A` `LMRRIAVV`        439013    F5R        HLA-A2                           HLA-A0201                     HLA-A0202    HLA-A0203    HLA-A0205    HLA-A0206    HLA-A6802
  `YLLSLFSTL`           439056    A35L       HLA-A2                           HLA-A0201                     HLA-A0202    HLA-A0203    HLA-A0205    HLA-A0206    HLA-A6802
  `YLAKLTALV`           438985    H5R        HLA-A2                           HLA-A0201                     HLA-A0202    HLA-A0203    HLA-A0205    HLA-A0206    HLA-A6802
  `NLLCHIYSL`           438979    K7L        HLA-A2                           HLA-A0201                     HLA-A0202    HLA-A0203    HLA-A0205    HLA-A0206    HLA-Cw0702
  `IVIEAIHTV`           439072    J2R        HLA-A0201                        HLA-A0201                     HLA-A0202    HLA-A0203    HLA-A0205    HLA-A0206    HLA-Cw0304
  `SLSAYIIRV`           439004    I3L        HLA-A0201                        HLA-A0201                     HLA-A0202    HLA-A0203    HLA-A0205    HLA-A0206    HLA-A0207
  `YLDGQLARL`           438965    E6R        HLA-A0201                        HLA-A0201                     HLA-A0202    HLA-A0203    HLA-A0205    HLA-A0206    HLA-A0207
  `YLPEVISTI`           438988    H7L        HLA-A0201                        HLA-A0201                     HLA-A0202    HLA-A0203    HLA-A0205    HLA-A0206    HLA-Cw0102
  `TYNDHIVNL`           439072    J2R        HLA-A2301                        HLA-A2301                     HLA-A2402    HLA-A2403    HLA-A2405    HLA-A2407    HLA-Cw0702
  `RPPSFYKPL`           439046    A25R       HLA-B7                           HLA-B0702                     HLA-B3501    HLA-B5101    HLA-B5301    HLA-B5401    HLA-Cw0102
  `ALDEKLFLI`           439045    A24R       HLA-A0201                        HLA-A0201                     HLA-A0202    HLA-A0203    HLA-A0205    HLA-A0206    HLA-A0207
  `FPYEGGKVF`           438968    E9L        HLA-B0702                        HLA-B0702                     HLA-B1502    HLA-B3501    HLA-B5101    HLA-B5301    HLA-B5401
  `RLYDYFTRV`           438973    K1L        HLA-A0201, HLA-A2                HLA-A0201                     HLA-A0202    HLA-A0203    HLA-A0205    HLA-A0206     
  `ILDDNLYKV`           438985    H5R        HLA-A0201, HLA-A2                HLA-A0201                     HLA-A0202    HLA-A0205    HLA-A0207    HLA-Cw0702    
  `LLSYYVVYV`           439009    F1R        HLA-A2                           HLA-A0201                     HLA-A0202    HLA-A0203    HLA-A0205    HLA-A0206     
  `FLIDLAFLI`           438960    E1L        HLA-A2                           HLA-A0202                     HLA-A0203    HLA-A0205    HLA-A0206    HLA-Cw0304    
  `FPRSMLSIF`           438994    M4R        HLA-B07:02                       HLA-B0702                     HLA-B3501    HLA-B4402    HLA-B5301    HLA-B5401     
  `YLFDFVISL`           438996    L1R        HLA-A2                           HLA-A0201                     HLA-A0202    HLA-A0203    HLA-A0205    HLA-A0206     
  `YLIKLIEPV`           439009    F1R        HLA-A0201, HLA-A2                HLA-A0201                     HLA-A0202    HLA-A0203    HLA-A0205    HLA-A0206     
  `SPSNHHILL`           439025    A4L        HLA-B07:02                       HLA-B0702                     HLA-B3501    HLA-B5101    HLA-B5301    HLA-B5401     
  `YPSNKNYEI`           439033    A12R       HLA-B07:02                       HLA-B0702                     HLA-B3501    HLA-B5101    HLA-B5301    HLA-B5401     
  `MLMETMFFI`           439007    I6R        HLA-A2                           HLA-A0201                     HLA-A0202    HLA-A0203    HLA-A0205    HLA-A0206     
  `ILNPVASSL`           438998    L3R        HLA-A2                           HLA-A0201                     HLA-A0202    HLA-A0205    HLA-A0206    HLA-B1501     
  `FPSVFINPI`           438968    E9L        HLA-B0702                        HLA-B0702                     HLA-B3501    HLA-B5101    HLA-B5301    HLA-B5401     
  `KYQSPVNIF`           439043    A21R       HLA-A24, HLA-class I             HLA-A2301                     HLA-A2402    HLA-A2403    HLA-A2405    HLA-A2407     
  `YLFGGFSTL`           438980    K8R        HLA-A2                           HLA-A0201                     HLA-A0202    HLA-A0203    HLA-A0205    HLA-A0206     
  `YLYETYHLI`           438981    H1L        HLA-A2                           HLA-A0201                     HLA-A0202    HLA-A0205    HLA-A0206                  
  `VLYNGVNYL`           439009    F1R        HLA-A2                           HLA-A0201                     HLA-A0202    HLA-A0205    HLA-A0206                  
  `LIQEIVHEV`           439029    A8L        HLA-A0201                        HLA-A0201                     HLA-A0202    HLA-A0205    HLA-A0206                  
  `VELGSGNSF`           439043    A21R       HLA-B3701                        HLA-B1501                     HLA-B1502    HLA-B4402    HLA-Cw0304                 
  `RMIAISAKV`           438934    P1L        HLA-A2                           HLA-A0201                     HLA-A0202    HLA-A0203    HLA-A0206                  
  `FILGIIITV`           439036    A15L       HLA-A0201                        HLA-A0202                     HLA-A0203    HLA-A0205    HLA-A0206                  
  `LLSKNTFYL`           438981    H1L        HLA-A2                           HLA-A0201                     HLA-A0202    HLA-A0205    HLA-A0207                  
  `RPRDAIRFL`           438961    E2L        HLA-B0702                        HLA-B0702                     HLA-B3501    HLA-B5301    HLA-B5401                  
  `KLFNKVPIV`           438996    L1R        HLA-A2                           HLA-A0201                     HLA-A0202    HLA-A0206    HLA-A6802                  
  `SLFMILCTR`           438979    K7L        HLA-A0301, HLA-A1101             HLA-A1101                     HLA-A3101    HLA-A3301    HLA-A6801                  
  `ILNDEQLNL`           439029    A8L        HLA-A0201                        HLA-A0201                     HLA-A0205    HLA-A0207                               
  `YLLGDSDSV`           439038    A17L       HLA-A2                           HLA-A0201                     HLA-A0205    HLA-A0206                               
  `QLMYALEPR`           438985    H5R        HLA-A0301, HLA-A1101             HLA-A3101                     HLA-A3301    HLA-A6801                               
  `LMDENTYAM`           439066    A45R       HLA-A2                           HLA-A0205                     HLA-A0207    HLA-Cw0702                              
  `GLLLGCFWV`           438955    C17L       HLA-A2                           HLA-A0202                     HLA-A0203    HLA-A0206                               
  `LLSHFYPAV`           438952    C14L       HLA-A2                           HLA-A0201                     HLA-A0205    HLA-A6802                              
  `NLFTFLHEI`           439045    A24R       HLA-class I                      HLA-A0201                     HLA-A0203    HLA-A0206                               
  `GLFDFVNFV`           439070    A49R       HLA-A2, HLA-A0201                HLA-A0202                     HLA-A0203    HLA-A0206                               
  `YLGPRVCWL`           439038    A17L       HLA-A2                           HLA-A0202                     HLA-A0205    HLA-A0206                               
  `ILKSLGFKV`           438980    K8R        HLA-A2                           HLA-A0202                     HLA-A0203    HLA-A0205                               
  `DEVASTHDW`           439025    A4L        HLA-B4403                        HLA-B4402                     HLA-B5801                                            
  `FLVIAINAM`           439029    A8L        HLA-A2, HLA-A0201                HLA-A0206                     HLA-Cw0304                                           
  `LSDLKKTIY`           439040    A19R       HLA-A1, HLA-class I              HLA-A0101                     HLA-B1501                                            
  `LLYFKVFGI`           439019    N1L        HLA-A2                           HLA-A0202                     HLA-A0205                                            
  `SSNIMSESY`           439014    F6R        HLA-A0101, HLA-A3002             HLA-A0101                     HLA-B1501                                            
  `DTRGIFSAY`           439032    A11L       HLA-A26, HLA-class I             HLA-A0101                     HLA-B5801                                            
  `QIDVEKKIV`           439029    A8L        HLA-A0201                        HLA-A0207                     HLA-A6802                                            
  `YLFRCVDAV`           439030    A9R        HLA-A2                           HLA-A0205                     HLA-A0206                                            
  `KIEDLINQL`           438973    K1L        HLA-A0201                        HLA-A0203                     HLA-A0207                                            
  `FTIDFKLKY`           439009    F1R        HLA-A1, HLA-A2601, HLA-A2902     HLA-A0101                     HLA-Cw0702                                           
  `WLKIKRDYL`           439074    J4R        HLA-B0801                        HLA-B0801                                                                          
  `AINVEKIEL`           473688    L6R        HLA-A0201                        HLA-A0207                                                                          
  `RIFVRVYNV`           439007    I6R        HLA-A2                           HLA-A0202                                                                          
  `SIIDLIDEY`           438942    C4R        HLA-B1501                        HLA-A0203                                                                          
  `EERHIFLDY`           439009    F1R        HLA-B4403                        HLA-B4402                                                                          
  `ILSDENYLL`           439028    A7L        HLA-A2, HLA-A0201                HLA-A0205                                                                          
  `HISALKRRY`           439027    A6R        HLA-A0101, HLA-A2902             HLA-A0101                                                                          
  `FLNISWFYI`           438968    E9L        HLA-A2, HLA-A02:01               HLA-A0205                                                                          
  `SEVKFKYVL`           439002    I1L        HLA-B44                          HLA-B4402                                                                          
  `KLLLWFNYL`           438980    K8R        HLA-A2                           HLA-A0203                                                                          
  `YIDISDVKV`           438973    K1L        HLA-A0201                        HLA-A0207                                                                          
  `VWINNSWKF`           439013    F5R        HLA-A24, HLA-A2301, HLA-A2402    HLA-Cw0702                                                                         
  `VLPFDIKKL`           439014    F6R        HLA-A0201                        HLA-Cw0102                                                                         
  `VETSISDYY`           439043    A21R       HLA-B3701                        HLA-B1501                                                                          
  `SQIIDISLR`           439022    A1L        HLA-A0301, HLA-A1101             HLA-B2705                                                                          
  `HDVYGVSNF`           439045    A24R       HLA-B4403                        HLA-B4402                                                                          

  CD4 T-cell epitope   VARV GI   VARV ORF   Experimental HLA II restriction   Predicted HLA II restriction                                                                                                                   
  -------------------- --------- ---------- --------------------------------- ------------------------------ ------------- ------------- ------------- ------------- ------------- ------------- ------------- ------------- -------------
  `FLIDLAFLI`          438960    E1L        HLA-class II                      DRB1*∗*0101                    DRB1*∗*0102   DRB1*∗*0301   DRB1*∗*0311   DRB1*∗*0401   DRB1*∗*1201   DRB1*∗*1302   DRB1*∗*1502   DRB3*∗*0101   DRB5*∗*0101
  `IHWQIISSE`          439072    J2R        DRB1*∗*04:05                      DRB1*∗*0405                    DRB1*∗*0406   DRB1*∗*0410   DRB1*∗*1304   DRB3*∗*0101                                                            
  `YIDAYVSRL`          439021    N3L        DRB1*∗*15:01                      DRB1*∗*0901                    DRB1*∗*1103   DRB3*∗*0202                                                                                        
  `LMDENTYAM`          439066    A45R       HLA-class II                      DRB1*∗*1103                                                                                                                                     
  `IDAYVSRLL`          439021    N3L        DRB1*∗*15:01                      DRB1*∗*1201                                                                                                                                     
  `RMIAISAKV`          438934    P1L        HLA-class II                      DRB1*∗*0407                                                                                                                                     

T-cell epitopes in this table are a subset of those provided in Additional File S1.

[^1]: Academic Editor: Jacek Tabarkiewicz
